Zusammenfassung
Indikationen, Wirkungsweise, Nebenwirkungen und Risiken, Kontraindikationen und Interaktionen werden für die Medikamente zur Behandlung von Abhängigkeit und Entzugssyndromen beschrieben. Der Aufbau dieses Kapitels unterscheidet sich insofern von den anderen Kapiteln als die einzelnen Suchtmittel die Struktur vorgeben.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Literatur
Andresen-Streichert H, Müller A, Glahn A et al (2018) Alkoholmarker bei klinischen und forensischen Fragestellungen. Dtsch Ärztebl 115(18):309–315
Anton RF, Latham P, Voronin K et al (2020) Efficacy of Gabapentin for the treatment of alcohol use disorder in patients with alcohol withdrawal symptoms: a randomized clinical trial. JAMA Intern Med 180(5):1–9
Barrio P, Ortega L, Guardia J et al (2018) Who receives nalmefene and how does it work in the real world? A single-arm, phase IV study of nalmefene in alcohol dependent outpatients: baseline and 1-month results. Clin Drug Investig 38(2):147–155
Bell J, Strang J (2020) Medication treatment of opioid use disorder. Biol Psychiatry 87(1):82–88
Black N, Stockings E, Campbell G et al (2019) Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. Lancet Psychiatry 6(12):995–1010
Bogenschutz MP, Ross S, Bhatt S et al (2022) Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry 79(10):953–962
Bschor T, Henssler J, Müller M, Baethge C (2018) Baclofen for alcohol use disorder – a systematic meta-analysis. Acta Psychiatr Scand 138(3):232–242
Carney G, Bassett K, Maclure M et al (2020) Cardiovascular and neuropsychiatric safety of smoking cessation pharmacotherapies in non-depressed adults: a retrospective cohort study. Addiction 115(8):1534–1546
Csajka C, Crettol S, Guidi M, Eap CB (2016) Population genetic-based pharmacokinetic modeling of methadone and its relationship with the QTc interval in opioid-dependent patients. Clin Pharmacokinet 55(12):1521–1533
Davies NM, Taylor GMJ, Taylor AE et al (2018) The effects of prescribing varenicline on two-year health outcomes: an observational cohort study using electronic medical records. Addiction 113(6):1105–1116
Desai RJ, Good MM, San-Juan-Rodriguez A et al (2019) Varenicline and nicotine replacement use associated with US Food and Drug Administration Drug Safety Communications. JAMA Netw Open 2(9):e1910626
Doran N, Dubrava S, Anthenelli RM (2019) Effects of varenicline, depressive symptoms, and region of enrollment on smoking cessation in depressed smokers. Nicotine Tob Res 21(2):156–162
D’Souza DC, Cortes-Briones J, Creatura G et al (2019) Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel group, phase 2a single-site randomised controlled trial. Lancet Psychiatry 6(1):35–45
EMA (2018) https://www.ema.europa.eu/en/documents/overview/buvidal-epar-medicine-overview_de.pdf. Zugegriffen: 14. Apr. 2023
Evins AE, Benowitz NL, West R et al (2019) Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with psychotic, anxiety, and mood disorders in the EAGLES trial. J Clin Psychopharmacol 39(2):108–116
Falk DE, O’Malley SS, Witkiewitz K et al (2019) Evaluation of drinking risk levels as outcomes in alcohol pharmacotherapy trials: a secondary analysis of 3 randomized clinical trials. JAMA Psychiatry 76(4):374–381
Gobbi G, Atkin T, Zytynski T et al (2019) Association of cannabis use in adolescence and risk of depression, anxiety, and suicidality in young adulthood. A systematic review and meta-analysis. JAMA Psychiatry 76(4):426–434
Gouzoulis-Mayfrank E, Härtel-Petri R, Hamdorf W et al (2017) Methamphetamine-related disorders. Dtsch Ärztebl Int 114(26):455–461
Heinz A, Gül Halil A, Gutwinski S et al (2022) ICD-11: Änderungen der diagnostischen Kriterien der Substanzabhängigkeit. Nervenarzt 93:51–58
Heinzerling KG, Swanson AN, Hall TM et al (2014) Randomized, placebo-controlled trial of bupropion in methamphetamine-dependent participants with less than daily methamphetamine use. Addiction 109(11):1878–1886
Hoch E, Friemel CM, Schneider M (Hrsg) (2018) Cannabis: Potential und Risiko. Ergebnisse einer wissenschaftlichen Analyse. Springer, Berlin, Heidelberg, New York
Hohmann N, Mikus G, Czock D (2014) Wirkungen und Risiken neuartiger psychoaktiver Substanzen. Dt Ärztebl 9:139–147
Kampman KM, Pettinati HM, Lynch KG et al (2013) A double-blind, placebo-controlled trial of topiramate for the treatment of comorbid cocaine and alcohol dependence. Drug Alcohol Depend 133(1):94–99
Kishi T, Sevy S, Chekuri R, Correll CU (2013) Antipsychotics for primary alcohol dependence: a systematic review and meta-analysis of placebo-controlled trials. Clin Psychiatry 74(7):e642–e654
Levin FR, Mariani J, Brooks DJ et al (2013) A randomized double-blind, placebo controlled trial of venlafaxine-extended release for co-occurring cannabis dependence and depressive disorders. Addiction 108(6):1084–1094
McKee KA, Hmidan A, Crocker CE et al (2021) Potential therapeutic benefits of cannabinoid products in adult psychiatric disorders: a systematic review and meta-analysis of randomised controlled trials. Psychiatr Res 140:267–281
Meier MH, Caspi A, Ambler A et al (2012) Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci USA 109(40):E2657–E2664
Nourredine M, Jurek L, Angerville B et al (2021) Use of topiramate in the spectrum of addictive and eating disorders: a systematic review comparing treatment schemes, efficacy, and safety features. Cns Drugs 35(2):177–213
Rankin GD, Wingfors H, Uski O et al (2019) The toxic potential of a fourth-generation E-cigarette on human lung cell lines and tissue explants. J Appl Toxicol 39(8):1143–1154
Rose JE, Behm FM (2014) Combination treatment with varenicline and bupropion in an adaptive smoking cessation paradigm. Am J Psychiatry 171(11):1199–1205
Rüther T, Wissen F, Linhardt A et al (2016) Electronic cigarettes – attitudes and use in Germany. Nicotine Tob Res 18(5):660–669
Santo T Jr, Campbell G, Gisev N et al (2022) Prevalence of mental disorders among people with opioid use disorder: a systematic review and meta-analysis. Drug Alcohol Depend 1:238
Sigmon SC, Dunn KE, Saulsgiver K et al (2013) A randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers. JAMA Psychiatry 70(12):1347–1354
Simpson TL, Saxon AJ, Stappenbeck C et al (2018) Double-blind randomized clinical trial of prazosin for alcohol use disorder. Am J Psychiatry 175(12):1216–1224
Soyka M (2016) Nalmefene for the treatment of alcohol use disorders: recent data and clinical potential. Expert Opin Pharmacother 17(4):619–626
Soyka M, Pogarell O (2019) Neue Slow-release-Buprenorphinformulierungen zur Optimierung der Opioidsubstitution. Nervenarzt 90(9):932–937
Squeglia LM, Tomko RL, Baker NL et al (2018) The effect of N-acetylcysteine on alcohol use during a cannabis cessation trial. Drug Alcohol Depend 185:17–22
Stapleton J, West R, Hajek P et al (2013) Randomized trial of nicotine replacement therapy (NRT), bupropion and NRT plus bupropion for smoking cessation: effectiveness in clinical practice. Addiction 108(12):2193–2201
Sullivan JT, Sykora K, Schneiderman J et al (1989) Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict 84(11):1353–1357
Verthein U, Beck T, Haasen C, Reimer J (2015) Mental symptoms and drug use in maintenance treatment with slow-release oral morphine compared to methadone: results of a randomized crossover study. Eur Addict Res 21(2):97–104
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature
About this chapter
Cite this chapter
Kiefer, F., Benkert, O. (2023). Medikamente zur Behandlung von Abhängigkeitserkrankungen und abhängigem Verhalten. In: Benkert, O., Hippius, H. (eds) Kompendium der Psychiatrischen Pharmakotherapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-67685-1_7
Download citation
DOI: https://doi.org/10.1007/978-3-662-67685-1_7
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-67684-4
Online ISBN: 978-3-662-67685-1
eBook Packages: Medicine (German Language)